Repligen Corporation
RGENNASDAQHealthcareMedical Instruments & Supplies
As of Oct 22, 2026 close
- Market cap
- $10.13B
- P/E (TTM)
- 243.77
- Forward P/E
- -
- Dividend yield
- -
- 52-week range
- $100.99$198.87
- Volume (live)
- -
- Avg. volume (3M)
- 1.22M
Repligen (RGEN) Stock Price & Financial Analysis
Repligen Stock Price Chart
Loading chart...
Financial Metrics & Key Statistics
Fundamental metrics, valuation ratios, and profitability indicators
| Day's Range | $175.96 - $185.03 |
|---|---|
| 52-Week High | $198.87 |
| 52-Week Low | $100.99 |
| Open | $179.45 |
| Volume (last close) | 1.27M |
| Average Volume (3M) | 1.22M |
| Revenue (TTM) | 785.10M |
|---|---|
| Net Income (TTM) | 41.54M |
| Free Cash Flow (TTM) | 110.78M |
| EPS (TTM) | $0.73 |
| Profit Margin | 5.29% |
| Operating Margin | 8.32% |
| Return on Equity (ROE) | 1.97% |
| Debt to Equity | 0.27 |
| Annual Dividend | $0.00 |
|---|---|
| Dividend Yield | 0.00% |
| Payout Ratio | 0.00% |
| Market Cap | 10.13B |
|---|---|
| Shares Outstanding | 56.66M |
| P/E Ratio (TTM) | 243.77 |
| Price to Sales (P/S) | 12.90 |
| Price to Book (P/B) | 4.79 |
| EV/EBITDA | 82.82 |
| 50-Day MA | $176.35 |
|---|---|
| 200-Day MA | $144.26 |
| 1-Year Change | +8.18% |
Source: Market prices and company fundamentals. Data as of Oct 22, 2026. Data sources and methodology
Repligen at a Glance
As of the Oct 22, 2026 close, Repligen (RGEN) has a market capitalization of $10.13B. The stock trades at 243.8× trailing earnings and 12.9× sales. Over the trailing twelve months it earned $41.54M on revenue of $785.10M (a 5.3% profit margin) and generated $110.78M of free cash flow. Revenue grew 16.5% year over year.
As of its latest reported balance sheet, it holds $606.78M in cash and securities against $570.36M of debt, a net cash position of $36.42M.
Repligen does not currently pay a dividend.
The share price is up 8.2% over the past year. At $178.71 (the Oct 22, 2026 close) it sits within its 52-week range of $100.99 to $198.87, above its 200-day moving average of $144.26.
Based on 12 professional analyst ratings from the past 90 days, the consensus is Buy with an average price target of $191.43, 7.1% above the Oct 22, 2026 close.
Frequently Asked Questions About Repligen
What is the current stock price for RGEN?
As of the Oct 22, 2026 close, RGEN stock trades at $178.71. The 52-week range is $100.99–$198.87, with a day range of $175.96–$185.03.
What is the P/E ratio for RGEN?
As of the Oct 22, 2026 close, Repligen's trailing twelve-month (TTM) P/E ratio is 243.8, meaning investors pay $243.8 for every $1 of annual earnings. Repligen operates in the Healthcare sector.
Does RGEN pay dividends?
Repligen does not currently pay a regular dividend. The company retains its earnings to reinvest in the business. Check the Dividends tab for historical dividend information.
What do analysts recommend for RGEN?
Based on ratings from 12 professional analysts over the last 90 days, the consensus for RGEN is Buy. The average 12-month price target is $191.43, a 7.1% upside from the Oct 22, 2026 close of $178.71.
What is the market cap of RGEN?
As of the Oct 22, 2026 close, Repligen's market capitalization is $10.13B, classifying it as a large-cap company. Repligen operates in the Healthcare sector within the Medical Instruments & Supplies industry.